Biodexa Pharmaceuticals Plc (BDRX) Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Biodexa Pharmaceuticals Plc NASDAQ:BDRX Healthcare · Biotechnology
Mkt Cap $3.53M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 2
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
Biodexa enrolled its 100th patient in the registrational Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis, out of a planned 168 subjects across 29 US and European sites.
CEO Stephen Stamp said the pre-specified futility analysis (after 25 PFS events) could occur early next year, with database lock (after 75 events) potentially around the end of next year — both significantly sooner than originally anticipated.
eRapa holds Orphan Drug Designation in the US and Europe; the program is supported by a $20 million CPRIT grant. Earlier futility timing cuts both ways for a small-cap biotech.
• 19d ago AI analysis › Press Release ● Major
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
accessnewswire.com • 1mo ago Press Release ⚠ 2
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
Biodexa Pharmaceuticals entered into a warrant exercise agreement with an existing accredited investor, bringing in approximately $2.3 million in gross proceeds.
In exchange for the immediate cash exercise of existing warrants on 2,204,218 ADSs at $1.05, the holder receives new unregistered warrants for up to 4,408,436 ADSs — twice the exercised amount — at the same $1.05 exercise price with a five-year term.
Maxim Group LLC acted as warrant inducement agent, and Biodexa agreed to file a resale registration statement covering the ADSs underlying the new warrants; closing was expected on or about September 15, 2026.
For a clinical-stage biotech with programs including eRapa, MTX240, and tolimidone, the transaction modestly extends the cash runway but doubles the warrant-related dilution overhang.
• 1mo ago AI analysis › Press Release ● Major ⚠ 7
Interim results for the six months ended June 30, 2026
Biodexa Pharmaceuticals reported unaudited 1H26 results with nil revenue, a net loss of £1.84 million (down from £3.81 million, though helped by a £2.38M derivative gain from the falling share price) and R&D costs up 75% to £2.92 million on the Serenta Phase 3 trial and the newly in-licensed MTX240 program.
Clinical execution advanced: 92 of a planned 168 subjects are enrolled in the registrational Phase 3 Serenta trial of eRapa in FAP, and management says passing 50% enrollment in early August puts it significantly ahead of competing development programs.
Cash was £3.23 million at June 30, 2026; on July 1 the company raised $3.5 million gross at US$2.85 per ADS with five-year warrants, but forecasts show further financing will be required during Q4 2026, with $26.08 million still undrawn on its $35 million ELOC.
Directors flagged a material uncertainty related to going concern, noted the market capitalization sits below Nasdaq's proposed $5 million minimum market value threshold, and disclosed a 10,000:1 share capital reorganization completed July 29, 2026.
• 1mo ago AI analysis › Press Release
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
Biodexa has recruited 87 subjects, exceeding 50% of its target of 168, for the registrational Phase 3 Serenta trial of eRapa in Familial Adenomatous Polyposis.
The trial is currently active at 29 clinical sites across the US and Europe, with a futility analysis planned after 25 Progression Free Survival events.
This Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.
• 2mo ago AI analysis › Press Release ⚠ 1
Result of General Meeting
Biodexa Pharmaceuticals announced the approval of four resolutions at its General Meeting, including a share reorganization that reduces the number of ordinary shares by a factor of 10,000 without changing proportional ownership.
The ADS ratio will change from 500,000:1 to 50:1 effective July 30, 2026, with approximately 51.5 million ordinary shares and 1.03 million ADSs outstanding post-reorganization.
Shareholders also granted directors the authority to allot ordinary shares on a non-pre-emptive basis.
• 3mo ago AI analysis › Press Release
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
Biodexa held a round table meeting in Paris to support Familial Adenomatous Polyposis (FAP) patients and prescribers, expanding its global initiative.
The company is making eRapa available via Early Access and Named Patient prescribing, targeting a condition with no currently approved therapeutic options.
The planned Phase 3 registrational trial is supported by a $20 million grant from CPRIT and aims to enroll 168 patients across 30 sites.
• 3mo ago AI analysis › Press Release ⚠ 1
Result of Annual General Meeting
Biodexa Pharmaceuticals reported the results of its re-scheduled Annual General Meeting, where ordinary resolutions 1 through 7 passed with majorities ranging from 73% to 94%.
Ordinary resolution 8 and special resolution 10 failed to secure approval, resulting in the failure of resolution 11 which was contingent on the passing of resolution 8.
The company continues to advance its clinical-stage pipeline, including eRapa for polyposis and bladder cancer, MTX240 for GIST, and tolimidone for type 1 diabetes.
• 4mo ago AI analysis › Press Release ⚠ 2
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
Biodexa Pharmaceuticals priced a $3.5 million financing package consisting of a $0.8 million registered direct offering, a $1.0 million private placement, and a $1.7 million warrant inducement.
The offering involves the sale of 282,952 ADSs and pre-funded warrants to purchase 350,877 ADSs at a price of $2.85 per share, alongside the issuance of new Series M, N, and O warrants covering an aggregate of 2,204,218 ADSs.
Proceeds are intended to fund development programs and working capital, with Maxim Group LLC acting as the sole placement agent.
• 4mo ago AI analysis › Press Release
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
Biodexa received Health Canada approval to expand its Phase 3 Serenta trial into Canada, adding three to four new clinical sites to the existing 29 active centers in the US and Europe.
Enrollment has accelerated to 73 patients out of a target of 168, supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas.
The registrational trial is evaluating eRapa, a proprietary oral formulation of rapamycin, for the treatment of familial adenomatous polyposis (FAP).
• 4mo ago AI analysis › Press Release ⚠ 1
Postponement and Re-scheduling of Annual General Meeting
Biodexa Pharmaceuticals has adjourned its Annual General Meeting scheduled for today due to a lack of a quorum.
The meeting has been rescheduled for June 30, 2026, at the Company's offices in Cardiff, with proxies submitted for the original meeting remaining valid.
Biodexa is a clinical-stage biopharmaceutical company developing products for the treatment of gastrointestinal cancers and type 1 diabetes.
• 4mo ago AI analysis › Press Release
Biodexa issues letter to Shareholders
globenewswire.com • 5mo ago Press Release ● Major
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
globenewswire.com • 6mo ago Press Release
Preliminary Results for the Year Ended 31 December 2025
globenewswire.com • 7mo ago Press Release ● Major
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
globenewswire.com • 7mo ago Press Release
ADR Ratio Change
globenewswire.com • 7mo ago Press Release
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
globenewswire.com • 7mo ago Press Release
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
accessnewswire.com • 8mo ago 
